Compugen (CGEN) FCF Margin (2009 - 2010)
Compugen's (CGEN) quarterly FCF Margin came in at 483.68% in Q4 2010, up 812032.0% year-on-year from N/an in Q4 2009, and up 94.38% quarter-over-quarter from 8604.0% in Q4 2009.
Compugen (CGEN) FCF Margin (2009 - 2010) Analysis & Trends
Compugen has disclosed FCF Margin across 2 years of filings, most recently posting 483.68% for Q4 2010.
- FCF Margin for Q4 2010 came in at 483.68%, up 812032.0% year-over-year; the trailing twelve-month figure through Dec 2010 was 116.5% (down 584428.0% YoY), and the FY2025 annual result was 43.05%, down 13454.0% from the prior year.
- FCF Margin came in at 483.68% for Q4 2010 at Compugen, up from 8604.0% in the prior quarter.
- In the past five years, FCF Margin ranged from a high of 981.25% in Q3 2009 to a low of 8604.0% in Q4 2009.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -3.98% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 43.35% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Compugen | 189.59 Mn | 97.83 Mn | 352,000.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2010 | -483.68% |
| Dec 31, 2009 | -8,604.00% |
| Sep 30, 2009 | 981.25% |